We quantified the rates of hepatic regeneration and functional recovery for 6 months after right hepatic lobectomy in living donors for liver transplantation. Twelve donors were studied pre-donation (baseline); 8 were retested at a mean 6 SD of 1163 days after donation (T1), 10 were retested at a mean of 9169 days after donation (T2), and 10 were retested at a mean of 185617 days after donation (T3). Liver and spleen volumes were measured with computed tomography (CT) and single-photon emission computed tomography (SPECT). Hepatic metabolism was assessed with caffeine and erythromycin, and hepatic blood flow (HBF) was assessed with cholates, galactose, and the perfused hepatic mass (PHM) by SPECT. The regeneration rates (mL kg 21 of body weight day 21 ) by CT were 0.6060.22 mL from the baseline to T1, 0.0560.02 mL from T1 to T2, and 0.0160.01 from T2 to T3; by SPECT they were 0.5460.20, 0.0460.01, and 0.0160.02, respectively. At T3, the liver volumes were 84%67% of the baseline according to CT and 92%613% of the baseline according to SPECT. Changes in the hepatic metabolism did not achieve statistical significance. At T1, the unadjusted clearance ratios with respect to the baseline were 0.7560.07 for intravenous cholate (P<0.001), 0.8860.15 for galactose (P50.07), 0.8460.08 for PHM (P50.002), and 0.8360.19 for the estimated HBF (P50.06). At T1, these ratios adjusted per liter of liver were up to 50% greater than the baseline values, suggesting recruitment of HBF by the regenerating liver. Increased cholate shunt, increased spleen volume, and decreased platelet count, were consistent with an altered portal circulation. In conclusion, initial hepatic regeneration is rapid, accounts for nearly two-thirds of total regeneration, and is associated with increases in HBF and cholate uptake. Right lobe donation alters the portal circulation of living donors, but the long-term clinical consequences, if there are any, are unknown.
usually complete within a few weeks. 4, 5 In these models, survival is linked to the rate and completeness of regeneration and the restoration of hepatic function.
Less is known about hepatic regeneration, hepatic function, and clinical outcomes in humans. Humar et al. 6 measured liver volumes by computed tomography (CT) 3 months after donation and found that the donor liver volume was 78.6% of the ideal, whereas the recipient liver volume was 103.9% of the ideal. Nadalin et al. 7 measured the volumes of donor remnants by magnetic resonance imaging (MRI) and found that the remnant volumes were 39% of the baseline immediately after resection, increased to 77% by 3 months, and were 83% of the baseline 1 year after donation. Pomfret et al. 8 performed CT studies at the baseline and 1 week and 1, 3, 6, and 12 months after donation. By 1 year, the liver volume was 83.3% of the baseline, and female donors had significantly less regeneration than male donors (79.8% versus 85.6%, P50.01). These studies suggest that the regeneration of donor remnants is incomplete.
Some studies have also evaluated the impact of donation on hepatic function. Nadalin et al. 7 studied the galactose elimination capacity (GEC) and found that the unadjusted GEC had declined 50% by day 10 but returned to the baseline at subsequent time points. The GEC adjusted for the remnant liver volume declined by less than 25% by day 10, was greater than the baseline at days 90 and 180, and returned to the baseline by day 360. Jochum et al. 9 had results similar to those of Nadalin et al.: GEC, expressed per kilogram of body weight, was 50% lower than the baseline value at day 10 and was nearly at the baseline by day 90. Jochum et al. also observed that the indocyanine green half-life increased, and the lidocaine half-life was not significantly altered. Neither study measured a broad array of liver functions, nor did they examine the relationships of function and regeneration.
In this study, we measured multiple hepatic functions, the hepatic blood flow (HBF), and the total liver and perfused liver volumes, and we related these results to the regeneration of the remnant left lobe during the first 6 months after right lobe donation.
PATIENTS AND METHODS

Patients
Donors were approached for participation in this study only after they had undergone a full evaluation for living donor liver transplantation, they had been approved by the selection committee for liver transplantation, and the date of the operation had been scheduled. Donors were recruited from 2 Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) clinical centers: the University of Colorado Denver and the University of California San Francisco.
The protocol was approved by the institutional review boards at the participating institutions, and all subjects provided written informed consent for both the main A2ALL study and this A2ALL-approved ancillary study.
Procedures, Test Compounds, and Analytical Methods
Participants maintained a caffeine-free, grapefruit juice-free, and alcohol-free diet for 3 days and were studied in the morning after an overnight fast at the general clinical research centers of the participating centers. An indwelling, intravenous 20-gauge catheter was placed for administering test compounds and sampling blood. Patients were supine during the study and minimized their activity.
The hepatic metabolism was quantified with erythromycin 10 and caffeine 11 as the test compounds.
Erythromycin Breath Test (EBT)
Three microcuries of [ 14 C-N-methyl]-erythromycin [product 02410806 (investigational new drug 31,760), Metabolic Solutions, Inc., Nashua, NH] was administered intravenously with a bolus injection, which was followed by a normal saline flush (10 mL). Breath samples for the measurement of 14 CO 2 generated from the hepatic metabolism of erythromycin were collected at the baseline and 20 minutes after dose administration with a T-tube apparatus, a capture solution, and an indicator dye. 12 14 CO 2 was quantified by radioscintigraphy, and the percentage of erythromycin metabolized per hour was determined.
Caffeine Elimination Rate and Clearance
Caffeine [300 mg; product 0072-5 (investigational new drug 65,175), Ruger Chemical Co., Irvington, NJ] was administered orally, and its hepatic metabolism was determined from the clearance measured via highperformance liquid chromatography of saliva samples obtained 2, 4, 8, and 12 hours after dosing. The distribution volume and the elimination rate were determined by a linear regression of the log e concentration versus time, and the clearance was the product of the distribution volume and the elimination rate.
The hepatic circulation was quantified with test compounds via flow-dependent, high first-pass hepatic extraction (galactose, 13 cholates, 14-17 and 99m Tc-cis-sulfur colloid [15] [16] [17] [18] ).
GEC
Galactose [30 g of low-endotoxin D-galactose; product G-105-1 (investigational new drug 65107), Pfanstiehl Laboratories, Inc., Waukegan, IL] in 100 mL of sterile water was administered intravenously over the course of 5 minutes. Blood samples were obtained at the baseline and 20, 40, 60, and 80 minutes after dosing, and the galactose concentration was quantified by spectrophotometry with a standardized lactose/D-galactose kit (catalog number 176 303, Boehringer Mannheim). GEC is the slope from the linear regression of the concentration versus the time.
Cholate Clearances and Shunt
Dual isotopes of cholate were simultaneously administered in an anionic form in bicarbonate solutions: one orally and the other intravenously. [14] [15] [16] [17] 14 and cholate isotopes were quantified by liquid chromatography-mass spectrometry. The cholate oral clearance and the cholate clearance after intravenous administration were calculated from the dose (40 mg for oral administration and 20 mg for intravenous administration) divided by the area under the concentration-time curves for each isotope (milligrams per minute per milliliter) and normalized for the body weight (kilograms), and the cholate shunt was the ratio of clearances for intravenously and orally administered isotopes. The estimated HBF was calculated with the following equation:
HBF 5ðCholate clearance after intravenous administration Þ= 12ðShunt =100 ð Þ ½ Þ 3 12 Hematocrit %=100ÞÞ ð ð An example of dual cholate clearance studies for one donor before and after donation is shown in Fig.  1 .
Single-Photon Emission Computed Tomography (SPECT) Liver-Spleen Scans
After the completion of blood sampling for the galactose and cholate tests, patients ingested a standard meal and 375 mL of Ensure (Abbott Laboratories, Abbott Park, IL) 30 minutes before the intravenous administration of 5 to 6 mCi of 99m Tc-cis-sulfur colloid with a particle size of 2 to 12 lm (CIS-US, Inc., Bedford, MA) for SPECT. [15] [16] [17] [18] SPECT studies were performed at the 2 clinical sites, and the data were transferred to the University of California Irvine for processing (J.C.H. and N.M.). The perfused hepatic mass (PHM), which was calculated from these images, was used to quantify the relative distribution of sulfur colloid between the liver, spleen and bone marrow. The liver and spleen volumes were also determined. [16] [17] [18] [19] [20] The organ volumes and the rates of hepatic regeneration were measured with both CT and SPECT liver-spleen scans.
Volumes From CT/MRI
CT studies and SPECT liver-spleen scans were performed on different days. Liver and spleen volumes were determined with the standard CT software algorithms used by the radiology departments at the participating clinical sites.
Volumes From SPECT
The liver and spleen volumes were also calculated from the SPECT reconstruction of images with the Hoefs method. [16] [17] [18] [19] [20] Each volume was derived from the total count in the liver or spleen from regions of interest around the summarized transaxial image and a representative organ concentration from a single transaxial slice through the division of the total hepatic or splenic count by the representative concentration.
The hepatic regeneration rates were defined as DV/Dt via both CT and SPECT, where DV is the change in the hepatic volume between consecutive time points and Dt is the time interval. The baseline volume was the liver volume measured before donation. The remnant liver volume on the day of donation [time 0 (T0)] was determined from baseline CT via the subtraction of the estimated right lobe graft volume from the total liver volume. For SPECT, we assumed the same proportionate size of the remnant with respect to the baseline that was estimated with CT. Regeneration rates were determined for each postdonation follow-up interval.
Clearance tests were expressed with respect to the body size (per kilogram) or liver size (per liter of liver). Changes in hepatic metabolism (microsomal function) were estimated from serial changes in caffeine clearance (cytochrome P450 1A2) and EBT results (cytochrome P450 3A4). Changes in total HBF were estimated from serial changes in GEC, the clearance of intravenously administered 24-13 C cholate, and SPECT liver-spleen scans. Alterations of the portal circulation were assessed through changes from the baseline in the clearance of orally administered 2,2,4,4-2 H cholate, the cholate shunt, the PHM from SPECT liver-spleen scans, the platelet count, and the spleen volume.
Statistical Analysis
Results are expressed as means, standard deviations, and ranges. Differences between baseline and postdonation results at T1, T2, and T3 and differences between post-donation time points were compared with 2-sided paired t tests. To test the relationship between platelet counts and spleen size, we used both linear regression and mixed model regression with subjects as random effects. Statistical analyses were performed at the data coordinating center for A2ALL (University of Michigan) with SAS 9.2 (SAS Institute, Cary, NC).
RESULTS
Twelve donors were studied at the baseline; 8 were retested at a mean of 1163 days after surgery (T1), 10 were retested at a mean of 9169 days after surgery (T2), and 10 were retested at a mean of 185617 days after surgery (T3). The mean age was 38 years (range521-54 years), the body mass index was 25.262.8 kg/m 2 , the male/female sex ratio was 4/8, and 10 donors were white. Table 1 displays the changes in routine laboratory tests over time after donation. All laboratory values were normal at the baseline. At T1, the bilirubin, prothrombin time international normalized ratio, and alanine aminotransferase values were higher than the baseline values, and the albumin value was lower. By T2, these tests were trending toward the baseline, and at T3, all had returned to the baseline values.
Standard Laboratory Tests
Total Liver Volume by CT Versus Perfused Liver Volume by SPECT
Volumes by CT are larger than those measured by SPECT. Using data from all time points, a linear regression through the origin of CT and SPECT volumes indicated that liver volumes by CT/MRI were approximately 22% larger (slope51.22, r50.93, P<0.001) and spleen volumes were 4% larger (slope51.04, r50.95, P<0.001) in comparison with SPECT volumes. The ratios of the perfused liver volume (by SPECT) to the total liver volume (by CT) were constant during regeneration (0.84-0.86), although they were slightly greater than the ratio at the baseline (0.78).
Regeneration Rates
The liver volumes at each time point (milliliters and milliliters/kilogram), the reconstitution of the baseline volume (V T /V predonation , where V T is the liver volume at study period T and V predonation is the predonation liver volume), and the rates of regeneration (milliliters per kilogram per day) are given in Table 2 . The relative changes in these parameters during regeneration were similar with CT and SPECT. The total liver volumes by CT at each time point (T0-T3) with respect to the predonation volumes are shown for each donor in Fig. 2A .
There were at least 2 phases of regeneration: an early rapid phase during the first 2 weeks and a slower later phase after the first 2 weeks. According to CT, the regeneration rates (mL kg 21 of body weight day 21 ) were 0.6060.22 from T0 to T1, 0.0560.02 from T1 to T2, and 0.0160.01 from T2 to T3 (Table 2) . According to SPECT, the regeneration rates were: 0.5460.20 from T0 to T1, 0.0460.01 from T1 to T2, and 0.0160.02 from T2 to T3 (Table 2) .
Approximately two-thirds of total hepatic regeneration occurred within the first 2 weeks after donation, and there was minimal regeneration after 3 months. At T3, approximately 6 months after donation, the liver volumes were 84%67% of the baseline according to CT and 92%613% of the baseline according to SPECT (Table 2 ).
Hepatic Metabolism
Changes in hepatic metabolism from the predonation baseline are shown in Table 3 . The total clearances of caffeine and erythromycin were slightly lower than the baseline at T1 and were slightly greater than the baseline at T2 and T3. After adjustments for the liver volume, the clearances of caffeine and erythromycin were increased above the baseline at T1, and this increase persisted through T2 and T3. However, none of these changes in the metabolism were statistically significant.
HBF Total unadjusted clearances of intravenously administered galactose, cholate, and 99m Tc-cis-sulfur-colloid (PMN by SPECT) and the calculated HBFs are displayed in Table 4 . These tests reflect the total blood flow to the remnant. At T1, the clearance of galactose (GEC) was 0.8860.15 of the predonation baseline (P50.07), the cholate clearance was 0.7560.07 of the baseline (P<0.001), PHM was 0.8460.08 of the baseline (P50.002), and HBF had decreased to 0.8360.19 of the baseline (P50.06). Thus, by 3 very different methods (GEC, dual cholate clearance, and SPECT), we demonstrated consistent and moderate decreases in total clearances and HBF at T1 without adjustments for the liver volume.
In contrast, when the clearances were adjusted for the liver volume and expressed per liter of liver, they were increased at T1 ( Table 4 ). The clearances per liter of liver for galactose, cholate, and 99m Tc-cis-sulfur colloid (relative change in HBF) were all increased above the baseline. These findings suggest that the early rapid phase of regeneration is associated with enhanced blood flow per unit of the regenerating liver.
Orally administered cholate is delivered to the portal circulation after its absorption from the intestine: changes in the clearance of orally administered cholate reflect changes in clearance from the portal circulation. Like the clearance of intravenous cholate, the total clearance of orally administered cholate was decreased at T1 (Table 5) , and this reflected the reduced hepatic mass. However, unlike the clearance of intravenous cholate, the clearance of orally administered cholate per liter of liver did not increase above the baseline at T1. The selective increase in the *For CT, the T0 volume was estimated from predonation CT scans via the subtraction of the right lobe volume from the total liver volume. For SPECT, the T0 volume was assumed to be proportionate to the predonation volume estimated by CT. Liver and spleen volumes are displayed both unadjusted and adjusted per kg body weight. †
The regeneration rate was calculated for each interval as follows: 
First-Pass Uptake of Cholate
We estimated the first-pass uptake of cholate from the fraction of the oral dose escaping hepatic extraction (corrected for the administered dose of cholate and normalized to the liver volume). At T1, during the period of rapid regeneration, we found a significant increase in the cholate uptake (2165 mg/L of liver at the baseline versus 3169 mg/L of liver at T1, P50.02). The cholate uptake at T2 (2564, P50.03) and T3 (2466, P50.06) approached the baseline values.
Alteration of the Portal Circulation
Several of our test results suggest that the portal circulation is altered after right lobe donation (Table 5) . At T1, the total clearance of orally administered cholate decreased (P<0.001), the cholate shunt increased (P50.03), and the platelet count decreased (P50.07). These changes persisted at T2 but, except for the platelet count, trended toward normal by T3. Paralleling the changes in the platelet count, the spleen volumes by both CT and SPECT increased by T1. The spleen volumes did not increase further, declined slightly, but remained above the baseline values throughout the study period ( Fig. 2B and Table  5 ). By T3, 6 months after donation, the CT spleen volume remained at 127%617% of the baseline (P<0.001), and the SPECT spleen volume remained at approximately 150% of the baseline (P50.02). The platelet count at T1 was 14% lower than the baseline, and it remained decreased through T3 ( Table 5 ). The platelet count was inversely related to the spleen volume ( Fig. 3 ). This relationship was significant when it was unadjusted (P<0.001) or adjusted (P50.002) for subject effects with a mixed model.
DISCUSSION
This prospective study examined longitudinal changes in multiple hepatic functions after the donation of the right hepatic lobe by living donors as well as functional changes uniquely related to the regeneration of the left lobe remnant. Ten of the 12 donors that we studied had an uncomplicated postoperative course as indicated by standard laboratory tests and a lack of clinical complications. As for the 2 donors with complications, one had a grade 2 urinary tract infection, and the other had a grade 1 pleural effusion and a grade 2 wound infection; all occurred in the first month after donation. Thus, our results for hepatic imaging, volume determination, and function testing can likely be applied to other donors undergoing right hepatic lobectomy with an uncomplicated or modestly complicated course.
We observed differences in liver volumes related to the differences in CT and SPECT imaging. CT images include all structures within the region of interest, including vascular, connective tissue, and biliary structures. SPECT images are based on the phagocytosis of 99m Tc-cis-sulfur colloid by the reticuloendothelial system and exclude nonparenchymal structures. The 22% lower volume measured by SPECT likely reflects its selectivity for parenchyma and PHM.
The rates of regeneration varied with the time after hepatic lobectomy. After lobectomy, the residual left lobe remnant was 31% of the baseline hepatic volume according to CT/MRI. In the first 2 weeks after donation, the hepatic volume nearly doubled, and the regeneration rate was 0.60 mL day 21 kg 21 of body weight by CT/MRI and 0.54 mL day 21 kg 21 of body weight by SPECT. Regeneration slowed dramatically after the first 2 weeks. During the following period of approximately 3 months, the regeneration rate was only 0.05 mL day 21 kg 21 of body weight by CT/MRI and 0.04 mL day 21 kg 21 of body weight by SPECT. The regeneration rate was even slower between 3 (T2) and 6 months (T3). In agreement with other studies, [6] [7] [8] [9] hepatic regeneration in the donors was incomplete. Six months after donation, the donors achieved only 84% (CT/MRI) to 92% (SPECT) of their baseline hepatic volumes. The dramatic differences in the regeneration rates between the time intervals suggests that factors regulating hepatic growth and, ultimately, the final liver volume must vary considerably between the early and later phases of regeneration. The early rapid phase of hepatic regeneration, from the baseline to T1, was associated primarily with 2 functional changes: an enhancement of HBF per gram of hepatic tissue and an increase in the hepatic uptake of cholate. Naturally, the total HBF must decrease with the removal of 60% of hepatic tissue, but the liver compensates by increasing local flow. The HBF per liter of liver was assessed by 3 independent measurements, which indicated up to a 50% increase in tissue blood flow. Thus, the blood flow per liter of tissue increased, and this helped to preserve blood flow-dependent hepatic function and partially compensate for the decrease in the total hepatic mass.
In contrast to the increase in the hepatic flow per liter of liver, the clearance of orally administered cholate per liter of liver, a marker of portal inflow, did not change. Taken together, these observations suggest that the enhancement of HBF is likely related to the selective recruitment of oxygen-rich hepatic arterial inflow. The importance of arterial perfusion in hepatic regeneration was emphasized recently in a rat model of ischemic injury. 21 In that model, hepatic arterial perfusion determined not only the extent of hepatic necrosis but also the formation of vascularized sinusoidal channels and parenchymal recovery. Figure 3 . Platelet counts and spleen volumes per kilogram of body weight before and after donation. The relationship between the platelet count and the spleen volume is shown, with the cutoff for a normal platelet count at 150 lL 21 . The results for studies performed at the baseline and at T1, T2, and T3 after donation are indicated by separate markers. There was an inverse relationship between the platelet count and the spleen volume. Another unique finding of our study was the selective enhancement of the hepatic uptake of orally administered cholate during early rapid hepatic regeneration. In animal models, activation of the primary nuclear bile acid receptor (farnesoid X receptor) by the hepatic flux of bile acids accelerates regeneration and inhibits genes of metabolism. [22] [23] [24] Thus, it is interesting that we measured a specific increase in the hepatic uptake of cholate during the early rapid phase of hepatic regeneration. We speculate that enhanced cholate uptake during the early phase of regeneration in living donors supports a role for bile acids in the regulation of human hepatic regeneration.
We did not observe statistically significant changes in the clearance or metabolism of 2 substrates of the cytochrome P450 system, caffeine and erythromycin. The immediate effect of hepatic resection is a reduction in the total hepatic metabolic capacity. 25 Our results indicated that 1163 days after donation, the hepatic metabolic capacity had returned to the baseline, and the metabolism of both caffeine and erythromycin per liter of liver had increased; this was consistent with compensatory up-regulation of hepatic cytochrome P450 enzymes. A study examining the acute phase response of cytochrome P450 enzymes after living donor liver transplantation found an early reduction at days 3 to 4 in EBT with a return to nearly the baseline around day 10. 26 Nonetheless, in the first several days after donation, it is likely that donors have a reduced total metabolic capacity due to the loss of hepatocyte mass and the immediate regenerative process. [22] [23] [24] [25] A clinical point worth emphasizing is that the dosing of medications cleared by hepatic metabolism should be adjusted downward to avoid excessive accumulation and toxicity during the first 1 to 2 weeks after donor hepatectomy.
An important observation of our study with potential clinical implications is the evidence pointing to an alteration of the portal circulation. Cholate shunt is a real-time measure of events in the portal circulation. There was an initial perturbation of the portal circulation with increased cholate shunt, which then trended toward normal by T2 and was at or near the baseline by T3. Other findings indicated a persistently altered portal circulation. The spleen volume increased by T1, trended downward by T2 and T3, but remained significantly above the baseline at T3. The increase in the spleen size was associated with a decreased platelet count; indeed, we found a significant inverse correlation between the platelet count and the spleen volume.
Others have also noted a relationship between the platelet count and the spleen size after living donation. 25, 27, 28 In these studies, a reduction in the platelet count was associated with normal or elevated levels of thrombopoeitin. 29 These findings and our results are consistent with hypersplenism from the persistence of an altered portal circulation and portal hypertension and suggest that long-term follow-up of donors and evaluations for manifestations of an altered portal circulation or portal hypertension may be warranted.
We conclude that there are at least 2 phases of hepatic regeneration. The early rapid phase of regeneration lasts for 2 weeks, accounts for two-thirds of total regeneration, and is associated with the recruitment of hepatic arterial inflow and enhanced uptake of bile acids. Right hepatic lobectomy alters the portal circulation; some of the changes are reversed, but others persist. Although the clinical implications of these findings are unknown, further long-term studies of the portal circulation of donors may be warranted.
